Suppr超能文献

血清MEPE-ASARM肽在X连锁佝偻病(低磷血症)中升高:对磷尿症和佝偻病的影响。

Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

作者信息

Bresler Doron, Bruder Jan, Mohnike Klaus, Fraser William D, Rowe Peter S N

机构信息

United States Air Force (USAF) Lackland, San Antonio, Texas, USA.

出版信息

J Endocrinol. 2004 Dec;183(3):R1-9. doi: 10.1677/joe.1.05989.

Abstract

MEPE (Matrix Extracellular PhosphoglycoprotEin) expression is markedly elevated in X-linked-hypophosphatemic-rickets (HYP) and tumor-induced osteomalacia (TIO). In normal individuals, circulating serum-levels of MEPE are tightly correlated with serum-phosphorus, parathyroid hormone (PTH) and bone mineral density (BMD). Also, MEPE derived, C-terminal ASARM-peptides are candidate minhibins and/or phosphatonins. Our aims were to determine: 1. whether MEPE-ASARM-peptide(s) are abnormally elevated in HYP/hyp serum, and, 2. whether the ASARM-peptide(s) accumulate in hyp mice kidney renal-tubules. Using a specific competitive ELISA we measured a five fold increase (P=0.007) of serum ASARM-peptide(s) in human HYP patients (normal subjects 3.25 microM n=9; S.E.M.=0.51 and HYP-patients 15.74 microM, n=9; S.E.M.=3.32). A 6.23 fold increase (P=0.008) was measured in hyp male mice compared with their normal male siblings (normal-siblings, 3.73 muM, S.E.M.=0.57, n=3; and hyp-mice 23.4 microM, n=3, S.E.M.=4.01). Renal immuno-histological screening also revealed a dramatic increase of ASARM-peptides in regions anatomically consistent with the proximal convoluted tubules. This study demonstrates for the first time that markedly elevated serum levels of protease-resistant ASARM-peptide(s) occur in HYP/hyp and they accumulate in murine hyp kidneys. These peptides are thus likely responsible for the phosphaturia and defective mineralization in HYP/hyp and TIO.

摘要

基质细胞外磷酸糖蛋白(MEPE)在X连锁低磷性佝偻病(HYP)和肿瘤诱导的骨软化症(TIO)中表达显著升高。在正常个体中,循环血清中MEPE水平与血清磷、甲状旁腺激素(PTH)和骨矿物质密度(BMD)密切相关。此外,MEPE衍生的C末端ASARM肽是候选的矿化抑制素和/或磷调节素。我们的目的是确定:1. 在HYP/低磷血清中MEPE-ASARM肽是否异常升高;2. ASARM肽是否在低磷小鼠的肾脏肾小管中积聚。使用特异性竞争ELISA,我们检测到人类HYP患者血清ASARM肽增加了5倍(P = 0.007)(正常受试者3.25μM,n = 9;标准误= 0.51;HYP患者15.74μM,n = 9;标准误= 3.32)。与正常雄性同胞相比,低磷雄性小鼠中检测到增加了6.23倍(P = 0.008)(正常同胞,3.73μM,标准误= 0.57,n = 3;低磷小鼠23.4μM,n = 3,标准误= 4.01)。肾脏免疫组织学筛查还显示,在与近端曲管解剖结构一致的区域,ASARM肽显著增加。这项研究首次证明,在HYP/低磷状态下,血清中抗蛋白酶的ASARM肽水平显著升高,并且它们在小鼠低磷肾脏中积聚。因此,这些肽可能是导致HYP/低磷和TIO中磷尿症和矿化缺陷的原因。

相似文献

3
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Crit Rev Eukaryot Gene Expr. 2012;22(1):61-86. doi: 10.1615/critreveukargeneexpr.v22.i1.50.
5
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.
Bone. 2006 Oct;39(4):773-86. doi: 10.1016/j.bone.2006.04.012. Epub 2006 Jun 9.
6
Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Bone. 2015 Oct;79:131-42. doi: 10.1016/j.bone.2015.05.030. Epub 2015 Jun 4.
8
ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
Am J Physiol Renal Physiol. 2011 Mar;300(3):F783-91. doi: 10.1152/ajprenal.00304.2010. Epub 2010 Dec 22.
9
SPR4-peptide alters bone metabolism of normal and HYP mice.
Bone. 2015 Mar;72:23-33. doi: 10.1016/j.bone.2014.11.011. Epub 2014 Nov 22.
10
MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Bone. 2004 Feb;34(2):303-19. doi: 10.1016/j.bone.2003.10.005.

引用本文的文献

1
X-linked hypophosphatemia, fibroblast growth factor 23 signaling, and craniosynostosis.
Exp Biol Med (Maywood). 2023 Nov;248(22):2175-2182. doi: 10.1177/15353702231222023. Epub 2024 Jan 17.
3
MiR-539-3p impairs osteogenesis by suppressing Wnt interaction with LRP-6 co-receptor and subsequent inhibition of Akap-3 signaling pathway.
Front Endocrinol (Lausanne). 2022 Sep 29;13:977347. doi: 10.3389/fendo.2022.977347. eCollection 2022.
4
Osteocytes and the pathogenesis of hypophosphatemic rickets.
Front Endocrinol (Lausanne). 2022 Sep 29;13:1005189. doi: 10.3389/fendo.2022.1005189. eCollection 2022.
5
FAM20C-Mediated Phosphorylation of MEPE and Its Acidic Serine- and Aspartate-Rich Motif.
JBMR Plus. 2020 Jun 26;4(8):e10378. doi: 10.1002/jbm4.10378. eCollection 2020 Aug.
6
Physiological Actions of Fibroblast Growth Factor-23.
Front Endocrinol (Lausanne). 2018 May 28;9:267. doi: 10.3389/fendo.2018.00267. eCollection 2018.
7
Regulatory roles of miRNA-758 and matrix extracellular phosphoglycoprotein in cervical cancer.
Exp Ther Med. 2017 Oct;14(4):2789-2794. doi: 10.3892/etm.2017.4887. Epub 2017 Aug 4.
8
Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
PLoS Biol. 2016 Apr 1;14(4):e1002427. doi: 10.1371/journal.pbio.1002427. eCollection 2016 Apr.
10
Downregulation of PHEX in multibacillary leprosy patients: observational cross-sectional study.
J Transl Med. 2015 Sep 11;13:296. doi: 10.1186/s12967-015-0651-5.

本文引用的文献

2
The wrickkened pathways of FGF23, MEPE and PHEX.
Crit Rev Oral Biol Med. 2004 Sep 1;15(5):264-81. doi: 10.1177/154411130401500503.
5
Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.
J Bone Miner Metab. 2004;22(3):176-84. doi: 10.1007/s00774-003-0468-9.
6
MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Bone. 2004 Feb;34(2):303-19. doi: 10.1016/j.bone.2003.10.005.
7
Hypophosphatemic rickets.
Endocr Dev. 2003;6:126-55. doi: 10.1159/000072774.
8
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
J Biol Chem. 2003 Sep 26;278(39):37419-26. doi: 10.1074/jbc.M304544200. Epub 2003 Jul 21.
10
Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.
J Biol Chem. 2003 Jan 17;278(3):1998-2007. doi: 10.1074/jbc.M203250200. Epub 2002 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验